- Home
- BCAB vs KALA Comparison
BCAB vs KALA Comparison
Compare BCAB & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- KALA
- Stock Information
- Founded
- BCAB 2007
- KALA 2009
- Country
- BCAB United States
- KALA United States
- Employees
- BCAB N/A
- KALA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- KALA Health Care
- Exchange
- BCAB Nasdaq
- KALA Nasdaq
- Market Cap
- BCAB 31.5M
- KALA 26.2M
- IPO Year
- BCAB 2020
- KALA 2017
- Fundamental
- Price
- BCAB $0.68
- KALA $17.47
- Analyst Decision
- BCAB Hold
- KALA Strong Buy
- Analyst Count
- BCAB 3
- KALA 3
- Target Price
- BCAB $1.00
- KALA $32.67
- AVG Volume (30 Days)
- BCAB 1.1M
- KALA 298.2K
- Earning Date
- BCAB 11-06-2025
- KALA 11-11-2025
- Dividend Yield
- BCAB N/A
- KALA N/A
- EPS Growth
- BCAB N/A
- KALA N/A
- EPS
- BCAB N/A
- KALA N/A
- Revenue
- BCAB $11,000,000.00
- KALA N/A
- Revenue This Year
- BCAB N/A
- KALA N/A
- Revenue Next Year
- BCAB N/A
- KALA N/A
- P/E Ratio
- BCAB N/A
- KALA N/A
- Revenue Growth
- BCAB N/A
- KALA N/A
- 52 Week Low
- BCAB $0.24
- KALA $2.92
- 52 Week High
- BCAB $2.53
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- BCAB 63.71
- KALA 72.92
- Support Level
- BCAB $0.60
- KALA $13.14
- Resistance Level
- BCAB $0.84
- KALA $15.66
- Average True Range (ATR)
- BCAB 0.08
- KALA 1.96
- MACD
- BCAB 0.02
- KALA 0.41
- Stochastic Oscillator
- BCAB 62.14
- KALA 71.93
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.